Morgan Stanley Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $116.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price increased by Morgan Stanley from $113.00 to $116.00 in a report released on Thursday morning, Benzinga reports. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.

ASND has been the topic of several other reports. Wedbush reissued an outperform rating and issued a $192.00 price objective on shares of Ascendis Pharma A/S in a report on Wednesday. StockNews.com downgraded Ascendis Pharma A/S from a hold rating to a sell rating in a research report on Wednesday. Cantor Fitzgerald reiterated an overweight rating and set a $152.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, September 15th. HC Wainwright reiterated a buy rating on shares of Ascendis Pharma A/S in a research report on Monday, October 9th. Finally, Wells Fargo & Company reduced their price objective on Ascendis Pharma A/S from $139.00 to $134.00 and set an overweight rating on the stock in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of Moderate Buy and a consensus price target of $141.38.

Ascendis Pharma A/S Trading Down 1.9 %

Shares of NASDAQ:ASND opened at $90.28 on Thursday. The business has a 50-day moving average price of $93.99 and a 200-day moving average price of $91.82. The company has a quick ratio of 2.65, a current ratio of 3.44 and a debt-to-equity ratio of 7.39. The stock has a market cap of $5.21 billion, a price-to-earnings ratio of -7.94 and a beta of 0.48. Ascendis Pharma A/S has a 52-week low of $64.33 and a 52-week high of $134.52.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Tuesday, September 5th. The biotechnology company reported ($2.35) earnings per share for the quarter, beating the consensus estimate of ($2.68) by $0.33. The company had revenue of $51.59 million during the quarter, compared to analysts’ expectations of $41.73 million. Ascendis Pharma A/S had a negative return on equity of 570.61% and a negative net margin of 391.76%. Equities analysts predict that Ascendis Pharma A/S will post -9.75 EPS for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors and hedge funds have recently modified their holdings of the company. Coppell Advisory Solutions LLC acquired a new position in Ascendis Pharma A/S during the 2nd quarter worth $45,000. Bessemer Group Inc. acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter worth about $58,000. Clearstead Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter worth about $66,000. SkyView Investment Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth about $66,000. Finally, BNP Paribas Arbitrage SA acquired a new position in shares of Ascendis Pharma A/S during the 2nd quarter worth about $67,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.